AAOS IDEA Grant Program Opens: Call for Proposals that Fuel the Future of Orthopaedics

Grant program inspires diversity, equity and access for educational, community and outreach initiatives. Application deadline is June 17, 2024

AAOS IDEA Grant Program

The American Academy of Orthopaedic Surgeons (AAOS) announced a call for proposals for the AAOS IDEA Grant Program ®, a multi-year initiative to inspire diversity, equity and access across the field of orthopaedics. Now in its third year, the program will award $300,000 in 2025 to help address decades of inertia surrounding persistent disparities across orthopaedics and, in turn, better serve patients nationwide.

“The programs selected for an AAOS IDEA Grant will help to cultivate meaningful and measurable opportunities across orthopaedics, acting as a springboard for change within our profession,” said AAOS Diversity Advisory Board Chair Holly Tyler-Paris Pilson, MD, FAAOS, FAOA. “This is not about checking a box; this call for proposals opens a door for funding directly to the local and regional orthopaedic programs and organizations who are training the current and next generation.”

The AAOS IDEA Grant Program tracks encompass a wide net to better fund and support a diverse pipeline of individuals who pursue orthopaedics as a profession; foster DEI initiatives for community-based or academic orthopaedic surgeons; and expand the availability of AAOS educational and networking opportunities to diverse students and practicing orthopaedic surgeons. Diversity focus areas of the program include gender, race/ethnicity, LGBTQ+, socioeconomic, veteran status and disability. Program funds will be allocated across four tracks, each with a different DEI focus and target recipient. Additional funding from AAOS supporters may be added to extend the reach of the initiative.
Grant proposals will remain open now through June 17, 2024, at 11:59 p.m. CT.

Applicants are encouraged to review the evaluation criteria and general application terms at aaos.org/IDEA. Grant recipients will be responsible for providing an outcomes report to AAOS to measure impact at the end of the funding period. To read about the 2023 and 2024 IDEA Grant Program recipients, click here or email media@aaos.org.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”